The Fair Trade Commission also considers filing a corporate complaint against 'Coupang PB Unfair Advantage'

Reporter Kim Jisun / approved : 2024-05-16 03:42:39
  • -
  • +
  • 인쇄

Coupang (photo = Yonhap news)

 

[Alpha Biz= Reporter Kim Jisun] It has been confirmed that the Fair Trade Commission, which has launched a sanctions process on Coupang's alleged unfair preferential treatment of its own brand (PB), is considering a "corporate complaint."

According to the industry on the 16th, the FTC previously filed a corporate complaint by sending a review report (the same as the prosecution's indictment) on Coupang's inducement of unfair customers through consumer fraud.

Coupang is suspected of inducing consumers' purchases by exposing PB products at the top regardless of the pre-announced ranking criteria in the product search basic setting 'Coupang ranking order'.

Contrary to consumers' general perception that ordinary consumers will buy products and write reviews, there are also suspicions that they actually deceived consumers by mobilizing executives and employees to write a large number of reviews.

The Fair Trade Commission, however, is said to have filed a complaint with the prosecution, believing that Coupang's operation of the algorithm constitutes a serious and intentional inducement of department customers.

Cases of violations of the Fair Trade Act can only be prosecuted by the prosecution if they are accused by the Fair Trade Commission, which has the exclusive right to file complaints.

 

 

Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)

어플

주요기사

Bomb Threats Target Major Korean Companies Including Samsung Electronics2025.12.19
FSS Raises Consumer Alert to “Warning” Over Secondary Scams Linked to Coupang Data Breach2025.12.19
Final U.S. Defense Authorization Bill Omits Provisions Supporting South Korea-Japan Shipbuilding Cooperation2025.12.19
Controversy Surrounds KT’s Former Outside Director Cho Seung-ah Amid Dual Directorship Issue2025.12.19
Samsung Securities Lowers LG Energy Solution Target Price to KRW 480,000 Amid Contract Cancellations2025.12.19
뉴스댓글 >

건강이 보이는 대표 K Medical 뉴스

HEADLINE

PHOTO

많이 본 기사